Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease

por Huguet, Jose María, Cortés, Xavier, Bosca-Watts, Marta Maia, Aguas, Marian, Maroto, Nuria, Martí, Lidia, Amorós, Cirilo, Paredes, Jose María
Publicado 2021

Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study

por Huguet, Jose M., García-Lorenzo, Victor, Martí, Lidia, Paredes, Jose María, Ramírez, Jose Joaquin, Pastor, Miguel, Ruiz, Lucia, Sanahuja, Ana, Timoneda, Pilar, Sanchís, Laura, Pérez, Gloria Alemany, Boscá-Watts, Marta Maia
Publicado 2022